Induction Agent and Incidence of Hypotension in Heart Failure Patients Undergoing LVAD-Implantation
NCT ID: NCT04934410
Last Updated: 2021-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2021-11-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This observational study aims to find out if the choice of the induction agent has a major impact on blood pressure and the use of antihypotensive drugs during the induction and the surgical procedure in heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients undergoing Implantation of left ventricular assist device (Etomidate)
High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is etomidate.
Etomidate
Use of etomidate during induction as decided by attending anesthesiologist
Patients undergoing Implantation of left ventricular assist device (Midazolam)
High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is midazolam.
Midazolam
Use of midazolam during induction as decided by attending anesthesiologist
Patients undergoing Implantation of left ventricular assist device (Sevoflurane)
High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is sevoflurane.
Sevoflurane
Use of sevoflurane during induction as decided by attending anesthesiologist
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etomidate
Use of etomidate during induction as decided by attending anesthesiologist
Midazolam
Use of midazolam during induction as decided by attending anesthesiologist
Sevoflurane
Use of sevoflurane during induction as decided by attending anesthesiologist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Presence of another cardiac assist device in the patient (for example ECLS)
* No consent of the patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heidelberg University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Adrian Stephan
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian E Stephan, MD
Role: STUDY_DIRECTOR
Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-602/2020
Identifier Type: -
Identifier Source: org_study_id